<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977570</url>
  </required_header>
  <id_info>
    <org_study_id>HA1806-CSP-002</org_study_id>
    <nct_id>NCT04977570</nct_id>
  </id_info>
  <brief_title>A Study of SYHA1805 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805 in Chinese Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of multiple-dose of SYHA1805.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics,&#xD;
      multiple ascending doses of SYHA1805 tablets or matching placebo tablets will be randomly&#xD;
      administered to 36 Chinese healthy subjects under fasting condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple-dose of SYHA1805</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>The safety and tolerability of multiple-dose of SYHA1805 administered orally will be assessed by incidence and severity of adverse events (AEs), ECG, changes in vital signs, physical Examination, and laboratory examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC）</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax）</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Peak Plasma Concentration (Cmax) after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration（Tmax）</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Time to maximum plasma concentration（Tmax）after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half time (t1/2)</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>The half time of SYHA1805 after administration are calculated under fasting conditions or under the food effect of high-fat, high-calorie meals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>To assess the apparent clearance (CL/F) after administration of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>SYHA1805</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will be randomized to receive the matching placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYHA1805 tablets</intervention_name>
    <description>Oral tablets of SYHA1805 with three pre-designed doses</description>
    <arm_group_label>SYHA1805</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets of placebo with matching doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 to 45 years of age inclusive;&#xD;
&#xD;
          -  Weight: Body weight ≥50 kg, body mass index (BMI) within the range of 19-28 kg/m2&#xD;
             (inclusive), BMI = weight (kg) / height 2 (m2);&#xD;
&#xD;
          -  Overtly healthy as determined by medical evaluation including comprehensive physical&#xD;
             examinations, vital signs, laboratory examinations, ECG examination, color Doppler&#xD;
             ultrasound (abdominal color Doppler ultrasound, heart color Doppler ultrasound), chest&#xD;
             X-ray, etc.;&#xD;
&#xD;
          -  Agree to use highly effective contraceptive methods (such as condoms or intrauterine&#xD;
             devices, contraceptive drugs) during the clinical trial period (screening period to 30&#xD;
             days after the last dose). Male subject refrains from sperm donation;&#xD;
&#xD;
          -  Fully understand the content and possible adverse reactions of the test drug, have the&#xD;
             ability to communicate with investigators normally, and able to comply with the&#xD;
             research requirements (such as: visit on time, and follow the procedures, restrictions&#xD;
             and requirements of the protocol);&#xD;
&#xD;
          -  Volunteer to participate in the study and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have history or other underlying risk factors of torsade de pointes ventricular&#xD;
             tachycardia, short QT syndrome, long QT syndrome. Have first-degree relatives&#xD;
             (biological parents, siblings or children) who suffered from sudden death in young age&#xD;
             (less than/equal to 40 years old), drowning or sudden infant death syndrome of unknown&#xD;
             cause;&#xD;
&#xD;
          -  Have history of malignant tumors, mental illness, depression, anxiety, and epilepsy;&#xD;
&#xD;
          -  Have history of drugs abuse in the past 3 years, or positive drug test at screening;&#xD;
&#xD;
          -  Have history of clinically significant drug allergies, or a history of atopic allergic&#xD;
             diseases (asthma, urticaria, eczema dermatitis), or those who are known to be allergic&#xD;
             to experimental drug excipients or the same type of drugs;&#xD;
&#xD;
          -  The investigator determines that the subjects have disease that affect drug&#xD;
             absorption, distribution, metabolism, or excretion, such as:&#xD;
&#xD;
               -  History of inflammatory bowel disease, gastritis, ulcers, bile duct stones,&#xD;
                  gastrointestinal or rectal bleeding;&#xD;
&#xD;
               -  History of major gastrointestinal surgery (gastrectomy, gastrointestinal&#xD;
                  anastomosis, or bowel resection);&#xD;
&#xD;
               -  History or clinical evidence of pancreatic injury or pancreatitis;&#xD;
&#xD;
               -  ALT, AST, or total serum bilirubin greater than 2 times the upper limits of&#xD;
                  normal (ULN) or other liver function test abnormalities during the screening&#xD;
                  period or the baseline period, and the abnormalities are determined by the&#xD;
                  investigator to have clinical significance, suggesting liver disease or liver&#xD;
                  damage;&#xD;
&#xD;
               -  Renal function suggests that the creatinine clearance rate is less than 90&#xD;
                  mL/min, or has urinary tract obstruction or difficulty in emptying urine during&#xD;
                  the screening period or the baseline period;&#xD;
&#xD;
          -  HBsAg positive, HCV-Ab positive, HIV-Ab positive or syphilis antibody positive during&#xD;
             the screening period;&#xD;
&#xD;
          -  Have history of alcohol abuse within 6 months before screening, have a positive&#xD;
             alcohol breath test during the screening period and the baseline period, or cannot&#xD;
             stop drinking during the entire study period; Subjects smoke more than 5 cigarettes&#xD;
             per day within the 3 months prior to screening, have a positive nicotine test at&#xD;
             screening, or cannot give up smoking during the entire study period;&#xD;
&#xD;
          -  Have participated in clinical trials of any drug or medical device within 3 months&#xD;
             before screening;&#xD;
&#xD;
          -  Have undergone major surgery within 3 months before screening, or have had severe&#xD;
             infections within 4 weeks before screening;&#xD;
&#xD;
          -  Have had significant change in diet or exercise habits within 3 months before&#xD;
             screening, such as weight loss, diet, exercise, etc.;&#xD;
&#xD;
          -  Donated blood ≥500 mL within 4 weeks before screening, or had severe blood loss in&#xD;
             excess of 500 mL, or received blood transfusion within 8 weeks prior to screening;&#xD;
&#xD;
          -  Have used any prescription drugs within the 4 weeks before screening, including&#xD;
             antibiotics or Chinese herbal medicines; have used any Over-the-Counter (OTC)&#xD;
             medications or food supplements (such as vitamins and calcium) within the 2 weeks&#xD;
             before screening except for paracetamol (maximum 1000 mg per day), ibuprofen (maximum&#xD;
             2400 mg per day) and topical OTC drugs; have taken a drug within its 5 half-lives&#xD;
             prior to the first dose of the study drug;&#xD;
&#xD;
          -  Smoking, consumption of alcohol or food/beverages containing xanthine or caffeine,&#xD;
             strenuous exercise, or taking foods that affect drug absorption, distribution,&#xD;
             metabolism, and excretion (such as grapefruit-containing drinks) within 2 days prior&#xD;
             to D-1 ;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Not suitable for this study as determined by the investigator due to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Lou, master</last_name>
    <role>Study Director</role>
    <affiliation>CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chanjuan Wang</last_name>
    <phone>15226599687</phone>
    <email>wangchanjuan@mail.ecspc.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

